2012-10-04 15:10:05 -

In an exclusive PropThink interview with ARIAD Pharmaceuticals (NASDAQ:ARIA),
CEO Harvey J. Berger discusses the company's lead product, ponatinib, a
potential treatment  for intolerant Chronic Myeloid Leukemia (CML) which was
submitted in full to the FDA for regulatory review in late September. Berger
explains that CML is an enormous market opportunity - upwards of $5 billion -
and that ponatinib has shown promising results as an important treatment option.
He discusses timeframes for an ongoing Phase III head-to-head trial of ponatinib
against Novartis' (NYSE:NVS) Gleevec, one of the primary CML treatments on the
market, and says that ponatinib is the first BCR-ABL inhibitor that blocks all
mutations and resistances in the protein. That trial, he says, may set the stage
for ponatinib to become a therapy for newly-diagnosed patients, and   compete with
drugs like Gleevec and Tasigna, both from Novartis, and Bristol-Myers Squibb's
(NYSE:BMY) Sprycel.

The interview also includes discussion of AP26113, ARIAD's early-stage drug for
Non Small-Cell Lung Cancer (NSCLC). While existing treatments such as Pfizer's
(NYSE:PFE) Xalkori ultimately fail at some point during treatment, Berger
believes AP26113 will overcome those resistances and shortcomings. The drug's
first clinical data was released in September, and Berger discusses the next
step in development, a pivotal trial for the treatment. He also mentions the
company's ambitious plan for product commercialization and the events that have
driven ARIAD to become a $4 billion company.

See Our Interview with ARIAD Pharmaceuticals by Clicking Here

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at  www.propthink.com.




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: PropThink via Thomson Reuters ONE
[HUG#1646348]